BTX
BlackRock Technology and Private Equity Term Trust
stockNYSE
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreements with Factor Bioscience and Novellus. Brooklyn's most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 8.74 | 2026-10-27 | -6.24% | 2.622 |
| 1M | 9.22 | 2026-10-02 | -11.12% | 2.468 |
| 3M | 8.25 | 2026-08-03 | -0.67% | 1.809 |
| 6M | 8.09 | 2026-05-04 | +1.30% | 1.923 |
| 1Y | 6.98 | 2025-11-03 | +17.41% | 1.764 |
| 2Y | 7.86 | 2025-02-20 | +4.26% | — |
| 5Y | 195.80 | 2021-11-03 | -95.81% | 0.935 |
BlackRock Technology and Private Equity Term Trust (NYSE:BTX) stock price today is $8.20, and today's volume is 685,146. BTX is down 1.621% today. The 30 day average volume is 501,099. BTX market cap is $956.44M with 116.71M shares outstanding.